Franz-Werner Haas, CureVac CEO (Thomas Kienzle/AFP via Getty Images)
November 17, 2022 11:02 AM EST
R&D

Cure­Vac puts lead on­col­o­gy can­di­date on back burn­er and will on­ly move it for­ward in com­bi­na­tion ther­a­pies

Paul Schloesser

Associate Editor

Cure­Vac is putting its lead can­cer ther­a­py on ice — for now.

The trans-at­lantic phar­ma with of­fices in Boston, MA and Ger­many put word of the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

GSK's Ze­ju­la-Jem­per­li com­bo in ovar­i­an can­cer hits pri­ma­ry end­point, miss­es on over­all sur­vival

A service from the Financial Times